Outcomes in Nonmetastatic Hormone Receptor–Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study
Journal of the National Comprehensive Cancer Network · 2024
DOI: 10.6004/jnccn.2023.7121 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024. Verfasst von Ryan Ying Cong Tan und 24 weiteren Autor:innen. Beteiligte Einrichtung: 1Division of Medical Oncology, National Cancer Centre Singapore, Singapore. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Adenocarcinoma, Mucinous, Receptors, Estrogen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Although considered a favorable subtype, pure mucinous breast cancer (PMBC) can recur, and evidence for adjuvant therapy is limited. We aimed to compare outcomes of nonmetastatic PMBC with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) to address these uncertainties.
Methods
Individual patient-level data from 6 centers on stage I–III hormone receptor–positive and HER2-negative PMBC, IDC, and ILC were used to analyze recurrence-free interval (RFI), recurrence-free survival (RFS), and overall survival (OS), and to identify prognostic factors for PMBC.
Results
Data from 20,684 IDC cases, 1,475 ILC cases, and 943 PMBC cases were used. Median follow-up was 6.6 years. Five-year RFI, RFS, and OS for PMBC were 96.1%, 94.9%, and 98.1%, respectively. On multivariable Cox regression, PMBC demonstrated superior RFI (hazard ratio [HR], 0.59; 95% CI, 0.43–0.80), RFS (HR, 0.70; 95% CI, 0.56–0.89), and OS (HR, 0.71; 95% CI, 0.53–0.96) compared with IDC. ILC showed comparable outcomes to IDC. Fewer than half (48.7%) of recurrences in PMBC were distant, which was a lower rate than for IDC (67.3%) and ILC (80.6%). In contrast to RFI, RFS events were driven more by non–breast cancer deaths in older patients. Significant prognostic factors for RFI among PMBC included positive lymph node(s) (HR, 2.42; 95% CI, 1.08–5.40), radiotherapy (HR, 0.44; 95% CI, 0.23–0.85), and endocrine therapy (HR, 0.25; 95% CI, 0.09–0.70). No differential chemotherapy associations with outcomes were detected across PMBC subgroups by nodal stage, tumor size, and age. A separate SEER database analysis also did not find any association of improved survival with adjuvant chemotherapy in these subgroups.
Conclusions
Compared with IDC, PMBC demonstrated superior RFI, RFS, and OS. Lymph node negativity, adjuvant radiotherapy, and endocrine therapy were associated with superior RFI. Adjuvant chemotherapy was not associated with better outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
- 2Duke-NUS Medical School, Singapore.
- 3Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore.
- 4Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- 5Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of South Korea.
- 6Division of Pathology, Singapore General Hospital, Singapore.
Zitieren
APA
Tan, R. Y. C., Ong, W. S., Lee, K. H., Park, S., Iqbal, J., Park, Y. H., Lee, J. E., Yu, J. H., Lin, C. H., Lu, Y. S., Ono, M., Ueno, T., Naito, Y., Onishi, T., Lim, G. H., Tan, S. M., Lee, H. B., Koh, J., Han, W., …, & Yap, Y. S. (2024). Outcomes in Nonmetastatic Hormone Receptor–Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2023.7121
Vancouver
Tan RYC, Ong WS, Lee KH, Park S, Iqbal J, Park YH, et al. Outcomes in Nonmetastatic Hormone Receptor–Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study. Journal of the National Comprehensive Cancer Network. 2024. doi:10.6004/jnccn.2023.7121
BibTeX
@article{Tan2024,
author = {Tan, Ryan Ying Cong and Ong, Whee Sze and Lee, Kyung-Hun and Park, Seri and Iqbal, Jabed and Park, Yeon Hee and Lee, Jeong Eon and Yu, Jong Han and Lin, Ching-Hung and Lu, Yen-Shen and Ono, Makiko and Ueno, Takayuki and Naito, Yoichi and Onishi, Tatsuya and Lim, Geok-Hoon and Tan, Su-Ming and Lee, Han-Byoel and Koh, Jiwon and Han, Wonshik and Im, Seock-Ah and Tan, Veronique Kiak Mien and Phyu, Nitar and Wong, Fuh-Yong and Tan, Puay Hoon and Yap, Yoon-Sim},
title = {Outcomes in Nonmetastatic Hormone Receptor–Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2024},
doi = {10.6004/jnccn.2023.7121}
}
EUVIMED